Iván R. González: Excellent article on the current situation and therapeutic options in desmoid tumors
Iván R. González, Medical Oncologist at Comprehensive Oncology Center, Hospital Ángeles Puebla, shared a post on X/Twitter:
“Excellent article on the current situation and therapeutic options in desmoid tumors: these are tumors with a tendency to infiltrate locally, which poses challenges in the choice of treatment due to the lack of a standardized approach.
For patients without symptoms, careful observation is recommended, as spontaneous regression has been observed in up to 20% of cases. Initial resection has lost preference due to the high morbidity and high relapse rates associated with these tumors.
Systemic therapy has undergone a shift from the use of chemotherapy to the application of tyrosine kinase and gamma-secretase inhibitors, offering an innovative mechanistic approach.
Benefits have also been observed with cryoablation and new inhibitors of the Wnt pathway.
The recent approval of nirogacestat marks a significant breakthrough, anticipating the arrival of more innovative treatments in the future. The wait-and-see strategy is advised for asymptomatic patients, while systemic therapy, such as sorafenib and nirogacestat, benefits those with symptoms.
Initial surgical resection and hormone therapy are not currently recommended. There are multiple molecules in development that target gamma-secretase and the Wnt pathway. Cryoablation is presented as a prominent localized option, although careful patient selection is required.”
Source: Iván R. González/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023